BIP_TRB2015_pegIFN

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis

Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.

Key Eligibilities:
-Diagnosis of MS made at least 3 months prior based on McDonald criteria.
-Ongoing treatment with PEG for 30 days or more at screening.
-Home access to microwave oven and freezer.

Exclusion Criteria:
-MS exacerbation within 60 days prior to screening.
-Contraindication to warm or cold compress, such as inability to sense temperature change by patient report or bleeding disorder.
-Concomitant use of any topical prescription medication at injection site.

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
N/A
NCT02490943
Neurosciences
Multiple Sclerosis
Kyle E Smoot, M.D.
EvergreenHealth
Eli Edwards
  • Providence St. Vincent Medical Center